Modified nucleotide triphosphates
A proven solution for mRNA therapeutic development
The use of modified nucleoside triphosphates (NTPs) has been instrumental in advancing mRNA therapeutic innovation, and TriLink® has been partnering with mRNA pioneers- since day one. Our modified NTPs are used in vaccine and therapeutic programs worldwide and continue to fuel the development of novel therapeutics. From research use to the first-ever GMP-grade offering, TriLink® provides a comprehensive portfolio of off-the-shelf, scalable, chemically synthesized NTP to help accelerate your mRNA therapeutic or vaccine development.
Promote robust expression and minimize immunogenicity
Incorporating modified uridines into mRNA products reduces immunogenicity, enhances mRNA stability, and increases translational capacity for more successful therapeutic action. TriLink’s broad catalog of 150+ modified NTPs, including N1-Methylpseudouridine-5’-Triphosphate,
5-Methoxyuridine-5’-Triphosphate, and Pseudouridine-5’-Triphosphate, are proven to optimize mRNA performance.
Highest-quality modified uridines for every stage and application
TriLink’s offerings of off-the-shelf, catalog, and customizable NTPs are available from RUO to GMP-grade to support diverse applications.
Related products and services
Our high-quality NTPs and dNTPs ensure robust results from PCR, RT-PCR, cDNA synthesis, sequencing, and in vitro mRNA transcription.
CleanCap® technology portfolio
CleanCap® analogs provide optimized co-transcriptional mRNA capping for vaccine and therapeutic applications.
mRNA CDMO services
TriLink’s discovery, preclinical, and clinical mRNA synthesis services help bring promising therapeutic candidates from the bench to the bedside.